Descriptive epidemiology of cholangiocarcinoma in Italy.

[1]  D. Alvaro.  Serum and bile biomarkers for cholangiocarcinoma , 2009, Current opinion in gastroenterology.

[2]  H. El‐Serag,et al.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population‐based study of U.S. veterans , 2009, Hepatology.

[3]  S. Yun,et al.  Hepatitis B Virus Infection and Intrahepatic Cholangiocarcinoma in Korea: A Case-Control Study , 2008, The American Journal of Gastroenterology.

[4]  G. Gores,et al.  Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment , 2008, Hepatology.

[5]  F. Lammert,et al.  Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers , 2008, Current opinion in gastroenterology.

[6]  P. Yachimski,et al.  Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. , 2008, Journal of clinical gastroenterology.

[7]  D. Alvaro,et al.  New insights on the molecular and cell biology of human cholangiopathies. , 2008, Molecular aspects of medicine.

[8]  S. Taylor-Robinson,et al.  Cholangiocarcinoma and its management , 2007, Gut.

[9]  A. Franchitto,et al.  Serum and Biliary Insulin-like Growth Factor I and Vascular Endothelial Growth Factor in Determining the Cause of Obstructive Cholestasis , 2007, Annals of Internal Medicine.

[10]  H. Sørensen,et al.  Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. , 2007, Journal of the National Cancer Institute.

[11]  T. Patel,et al.  Cholangiocarcinoma: emerging approaches to a challenging cancer , 2007, Current opinion in gastroenterology.

[12]  Yusuke Nakamura,et al.  Comparison of gene expression profiles between Opisthorchis viverrini and non‐Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma , 2006, Hepatology.

[13]  T. O'Brien,et al.  Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. , 2006, Journal of the National Cancer Institute.

[14]  K. McGlynn,et al.  A Comparison of Trends in the Incidence of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.

[15]  J. West,et al.  Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001 , 2006, British Journal of Cancer.

[16]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[17]  Yusuke Nakamura,et al.  Genome‐wide analysis of gene expression in human intrahepatic cholangiocarcinoma , 2005, Hepatology.

[18]  E. Schrumpf,et al.  Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. , 2004, Journal of hepatology.

[19]  K. Lindor,et al.  Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis , 2004, American Journal of Gastroenterology.

[20]  K. McGlynn,et al.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.

[21]  P. Hayes,et al.  Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. , 2003, European journal of cancer.

[22]  K. Lillemoe,et al.  Identification of novel cellular targets in biliary tract cancers using global gene expression technology. , 2003, The American journal of pathology.

[23]  C. Larsson,et al.  A protein kinase Cβ inhibitor attenuates multidrug resistance of neuroblastoma cells , 2003, BMC Cancer.

[24]  T. Patel,et al.  Worldwide trends in mortality from biliary tract malignancies , 2002, BMC Cancer.

[25]  P. Sauer,et al.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. , 2002, Journal of hepatology.

[26]  K. Boberg,et al.  Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation , 2002, Scandinavian journal of gastroenterology.

[27]  T. Patel.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[28]  W. Kremers,et al.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.

[29]  D. Parkin,et al.  Liver cancer in Thailand. I. A case‐control study of cholangiocarcinoma , 1991, International journal of cancer.

[30]  S. Glaser,et al.  Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. , 2007, Gastroenterology.

[31]  S. Wallerstedt,et al.  Incidence, etiologic aspects and clinicopathologic features in intrahepatic cholangiocellular carcinoma--a study of 51 cases from a low-endemicity area. , 1998, Acta oncologica.